Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to pioneering the development of genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. The company's mission is to lead the next revolution in cell therapy by delivering the first "off-the-shelf" allogeneic CAR T (AlloCAR T) products. Allogene Therapeutics is headquartered in South San Francisco, California.

Allogene is focused on developing a pipeline of "off-the-shelf" CAR T cell product candidates, which are derived from healthy donors for use in any patient, aiming to overcome the logistical and manufacturing limitations of patient-specific autologous therapies. Its key product candidates include cemacabtagene ansegedleucel (cema-cel) for Large B-Cell Lymphoma (LBCL), ALLO-316 for Renal Cell Carcinoma (RCC), and ALLO-329 for autoimmune diseases.

David Chang, M.D., Ph.D., serves as the President, CEO, and Co-Founder of Allogene Therapeutics. The company recently reported a positive interim futility analysis from its pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL, demonstrating 58.3% MRD clearance. In April 2026, Allogene completed a public offering of common stock, raising $200.4 million, which is expected to extend its cash runway into the first quarter of 2028. Initial human translational data for ALLO-329 in autoimmune diseases are anticipated in June 2026. Allogene is positioned as a leader in the allogeneic CAR T therapy space, striving to provide more accessible and scalable cell therapy options.